I am executingexpress
I am executingestimate
[1.0, 2.0, 667.0, 5.0, 'online . All rates are  <expressed>  as age-standardised based on ', 0.009727626459143969, 1]
[1.0, 3.0, 161.0, 5.0, 'the GBD study, particularly estimates  <expressed>  in terms of population ', 0.1388888888888889, 1]
[1.0, 3.0, 424.0, 5.0, 'prevalence, and YLDs of injuries  <expressed>  only in terms of ', 0.016722408026755852, 1]
[1.0, 4.0, 320.0, 1.0, '2.1 did not capture the  <complexity>  of the disease or ', 0.004901960784313725, 1]
[1.0, 71.0, 226.0, 1.0, 'to a certain extent the  <complexity>  of rural societies, as ', 0.008403361344537815, 1]
[1.0, 56.0, 79.0, 1.0, 'Kassa, Getachew Mullu Kassa, Tesfaye  <Dessale>  Kassa, Nicholas J Kassebaum, ', 0.025, 1]
[1.0, 61.0, 862.0, 1.0, 'Medical Education, Tehran, Iran (A  <Khosravi>  PhD); Center of Excellence ', 0.0015503875968992248, 1]
[1.0, 0.0, 180.0, 6.0, 'of high-quality data. Methods We  <estimated>  incidence and prevalence for ', 0.42857142857142855, 1]
[1.0, 0.0, 305.0, 6.0, 'for each condition. YLDs were  <estimated>  as the product of ', 0.04316546762589928, 1]
[1.0, 0.0, 312.0, 6.0, 'the product of a prevalence  <estimate>  and a disability weight ', 0.0410958904109589, 1]
[1.0, 1.0, 604.0, 6.0, 'to cause-specific mortality rates to  <estimate>  incidence, and then calculated ', 0.02181818181818182, 1]
[1.0, 2.0, 374.0, 6.0, 'health loss over time and  <estimate>  the statistical differences in ', 0.027149321266968326, 1]
[1.0, 2.0, 773.0, 6.0, 'Norway, Russia) and countries previously  <estimated>  at subnational levels (GBD ', 0.00967741935483871, 1]
[1.0, 3.0, 238.0, 6.0, 'causes, increasing the number of  <estimated>  causes in GBD to ', 0.05309734513274336, 1]
[1.0, 3.0, 249.0, 6.0, 'with 282 causes of death  <estimated>  and 354 causes of ', 0.04838709677419355, 1]
[1.0, 4.0, 362.0, 6.0, '1 section 4). Prevalence was  <estimated>  for nine impairments, defined ', 0.024390243902439025, 1]
[1.0, 4.0, 379.0, 6.0, 'better data were available to  <estimate>  the overall occurrence than ', 0.022813688212927757, 1]
[1.0, 5.0, 248.0, 6.0, '2016. YLD computation YLDs were  <estimated>  as the product of ', 0.04838709677419355, 1]
[1.0, 5.0, 254.0, 6.0, 'as the product of prevalence  <estimate>  and a disability weight ', 0.046153846153846156, 1]
[1.0, 5.0, 369.0, 6.0, 'are computed using the mean  <estimate>  across 1000 draws, and ', 0.024489795918367346, 1]
[1.0, 38.0, 691.0, 6.0, 'Blank cells mean that no  <estimate>  is available or that ', 0.013452914798206279, 1]
[1.0, 38.0, 697.0, 6.0, 'is available or that the  <estimate>  has a magnitude less ', 0.01327433628318584, 1]
[1.0, 42.0, 66.0, 6.0, 'loss, calculated as the female-specific  <estimate>  subtracted from the male-specific ', 1.5, 1]
[1.0, 42.0, 71.0, 6.0, 'estimate subtracted from the male-specific  <estimate>  such that causes on ', 0.6666666666666666, 1]
[1.0, 48.0, 761.0, 6.0, 'in the GBD study, we  <estimated>  the burdens of type ', 0.03278688524590164, 1]
[1.0, 48.0, 933.0, 6.0, 'cancer caused by NASH, we  <estimated>  892 million (95% UI ', 0.016901408450704224, 1]
[1.0, 51.0, 389.0, 6.0, 'Walker and colleagues’ study 81  <estimated>  1·7 billion episodes of ', 0.015957446808510637, 1]
[1.0, 51.0, 412.0, 6.0, 'greater than the GBD 2017  <estimate>  in the same year ', 0.015037593984962405, 1]
[1.0, 51.0, 431.0, 6.0, 'by Rudan and colleagues 82  <estimated>  a global pneumonia incidence ', 0.014354066985645933, 1]
[1.0, 51.0, 465.0, 6.0, 'greater than the GBD 2017  <estimate>  of 94·5 million (79·5–112). ', 0.01327433628318584, 1]
[1.0, 51.0, 685.0, 6.0, 'countries with representative surveys. Our  <estimated>  global prevalence results are ', 0.008928571428571428, 1]
[1.0, 52.0, 357.0, 6.0, 'of acute malnutrition than was  <estimated>  previously. Diabetes Diabetes has ', 0.027522935779816515, 1]
[1.0, 52.0, 363.0, 6.0, 'previously. Diabetes Diabetes has been  <estimated>  in previous GBD studies, ', 0.026785714285714284, 1]
[1.0, 52.0, 382.0, 6.0, 'and type 2 diabetes were  <estimated>  and reported separately. The ', 0.024691358024691357, 1]
[1.0, 52.0, 472.0, 6.0, 'for the first time we  <estimated>  NASH as a cause ', 0.018018018018018018, 1]
[1.0, 52.0, 493.0, 6.0, 'state. Our global age-standardised prevalence  <estimate>  of NAFLD and NASH ', 0.01694915254237288, 1]
[1.0, 52.0, 530.0, 6.0, 'by Younossi and colleagues,86 which  <estimated>  a global prevalence of ', 0.015345268542199489, 1]
[1.0, 53.0, 246.0, 6.0, 'poisoning by other agents. Our  <estimate>  of 172 million (95% ', 0.044444444444444446, 1]
[1.0, 53.0, 270.0, 6.0, 'than those of WHO, which  <estimated>  37 million falls 88 ', 0.03773584905660377, 1]
[1.0, 53.0, 505.0, 6.0, 'treatment access. As such, YLDs  <estimated>  might not reflect improvements ', 0.015228426395939087, 1]
[1.0, 53.0, 869.0, 6.0, 'random effects for geographies to  <estimate>  a prior distribution ', 0.0079155672823219, 1]
[1.0, 0.0, 227.0, 5.0, 'of death models to inform  <estimates>  using a total of ', 0.08196721311475409, 1]
[1.0, 0.0, 549.0, 5.0, 'in terms of age-standardised prevalence  <estimates>  for multiple causes. The ', 0.013054830287206266, 1]
[1.0, 1.0, 458.0, 5.0, 'sources being used in the  <estimation>  process for GBD 2017 ', 0.03875968992248062, 1]
[1.0, 1.0, 466.0, 5.0, 'GBD 2017 . We improved  <estimation>  methods including updating the ', 0.0364963503649635, 1]
[1.0, 1.0, 497.0, 5.0, 'females, using internally consistent GBD  <estimates>  of population and fertility, ', 0.02976190476190476, 1]
[1.0, 1.0, 573.0, 5.0, 'to the inpatient admission per-capita  <estimates>  to more accurately measure ', 0.020491803278688523, 1]
[1.0, 1.0, 734.0, 5.0, 'poisoning by other means; and  <estimates>  for natures of injury ', 0.012345679012345678, 1]
[1.0, 2.0, 306.0, 5.0, 'on an annual basis, new  <estimates>  are provided not only ', 0.032679738562091505, 1]
[1.0, 2.0, 313.0, 5.0, 'provided not only for new  <estimation>  years but also for ', 0.03125, 1]
[1.0, 2.0, 320.0, 5.0, 'but also for all previous  <estimation>  years and supersede any ', 0.029940119760479042, 1]
[1.0, 2.0, 338.0, 5.0, 'incorporates improvements in study design,  <estimation>  strategy, and data availability, ', 0.02702702702702703, 1]
[1.0, 2.0, 396.0, 5.0, 'provides a standardised approach for  <estimating>  incidence, prevalence, and YLDs ', 0.0205761316872428, 1]
[1.0, 2.0, 452.0, 5.0, 'find a consistent set of  <estimates>  between data on prevalence, ', 0.016722408026755852, 1]
[1.0, 2.0, 465.0, 5.0, 'of death; and to predict  <estimates>  for locations and causes ', 0.016025641025641024, 1]
[1.0, 2.0, 586.0, 5.0, 'classes of alternative approaches for  <estimating>  non-fatal health outcomes, including ', 0.011547344110854504, 1]
[1.0, 2.0, 658.0, 5.0, 'Statistical code used for GBD  <estimation>  is publicly available online ', 0.009900990099009901, 1]
[1.0, 2.0, 745.0, 5.0, 'and continues to provide subnational  <estimates>  for countries that were ', 0.008445945945945946, 1]
[1.0, 2.0, 756.0, 5.0, 'in previous cycles. S ubnational  <estimation>  in GBD 2017 includes ', 0.008291873963515755, 1]
[1.0, 2.0, 842.0, 5.0, 'local government authorities). All subnational  <estimates>  for these countries were ', 0.00725689404934688, 1]
[1.0, 2.0, 871.0, 5.0, 'publication we present all subnational  <estimates>  excluding those pending See ', 0.006963788300835654, 1]
[1.0, 3.0, 154.0, 5.0, 'and population estimates, which affect  <estimates>  throughout the GBD study, ', 0.1724137931034483, 1]
[1.0, 3.0, 160.0, 5.0, 'throughout the GBD study, particularly  <estimates>  expressed in terms of ', 0.14285714285714285, 1]
[1.0, 3.0, 174.0, 5.0, 'of using internally derived demographic  <estimates>  is to ensure internal ', 0.10204081632653061, 1]
[1.0, 3.0, 312.0, 5.0, '4 causes. We also report  <estimates>  for 3484 sequelae, nine ', 0.026737967914438502, 1]
[1.0, 3.0, 504.0, 5.0, 'sources The process for non-fatal  <estimation>  begins with the compilation ', 0.013192612137203167, 1]
[1.0, 3.0, 713.0, 5.0, 'were then combined in the  <estimation>  process. The supplementary methods ', 0.008503401360544218, 1]
[1.0, 3.0, 869.0, 5.0, 'of admissions that inform GBD  <estimation>  to more than 2·6 ', 0.006720430107526882, 1]
[1.0, 4.0, 418.0, 5.0, 'were used for each impairment  <estimation>  process; these details are ', 0.016556291390728478, 1]
[1.0, 5.0, 291.0, 5.0, 'from conditions that lack specific  <estimation>  models. Uncertainty analysis We ', 0.029940119760479042, 1]
[1.0, 5.0, 363.0, 5.0, 'distributions and disability weights. Final  <estimates>  are computed using the ', 0.02092050209205021, 1]
[1.0, 5.0, 407.0, 5.0, 'is a summary measure that  <estimates>  a location’s position on ', 0.0176678445229682, 1]
[1.0, 5.0, 478.0, 5.0, 'minima and maxima over the  <estimation>  period to set the ', 0.014124293785310734, 1]
[1.0, 5.0, 654.0, 5.0, 'were then computed using country-level  <estimates>  of SDI for 2017, ', 0.009433962264150943, 1]
[1.0, 5.0, 780.0, 5.0, 'prevalence, incidence, and YLDs Non-fatal  <estimates>  by cause for 354 ', 0.007621951219512195, 1]
[1.0, 38.0, 747.0, 5.0, 'in HIV positive cases. ‡Incidence  <estimates>  for stroke represent first-ever ', 0.0099601593625498, 1]
[1.0, 48.0, 773.0, 5.0, 'type 2 diabetes separately. Our  <estimates>  illustrate the emergence of ', 0.02564102564102564, 1]
[1.0, 48.0, 906.0, 5.0, 'the first year of GBD  <estimation>  for non- alcoholic fatty ', 0.01524390243902439, 1]
[1.0, 49.0, 582.0, 5.0, 'appendix 2). GBD risk factor  <estimates>  show that the drivers ', 0.010638297872340425, 1]
[1.0, 51.0, 247.0, 5.0, 'this year’s study is the  <estimation>  of population and fertility ', 0.021367521367521368, 1]
[1.0, 51.0, 379.0, 5.0, 'attributions. Our overall diarrhoea incidence  <estimates>  were not affected. The ', 0.01366120218579235, 1]
[1.0, 51.0, 543.0, 5.0, 'which include location-specific and year-specific  <estimates>  of risk factors associated ', 0.009433962264150943, 1]
[1.0, 51.0, 736.0, 5.0, '1 section 4). The hepatitis  <estimation>  process has changed to ', 0.006915629322268326, 1]
[1.0, 51.0, 748.0, 5.0, 'consistency between mortality and non-fatal  <estimates>  for GBD 2017 . ', 0.006802721088435374, 1]
[1.0, 51.0, 860.0, 5.0, 'rather than in the prevalence  <estimates>  for acute hepatitis B ', 0.0059031877213695395, 1]
[1.0, 52.0, 159.0, 5.0, 'birth defects. Adopting in-facility delivery  <estimates>  for processing clinical data ', 0.25, 1]
[1.0, 52.0, 170.0, 5.0, 'maternal disorders led to lower  <estimates>  of pregnancy compli - ', 0.16129032258064516, 1]
[1.0, 52.0, 185.0, 5.0, 'We refined our method for  <estimating>  age-specific preterm birth and ', 0.10869565217391304, 1]
[1.0, 52.0, 219.0, 5.0, 'enforced internal consistency among our  <estimates>  such that, for example, ', 0.0625, 1]
[1.0, 52.0, 251.0, 5.0, 'methodological changes have lowered global  <estimates>  for many of the ', 0.044642857142857144, 1]
[1.0, 52.0, 387.0, 5.0, 'estimated and reported separately. The  <estimation>  strategy for diabetes is ', 0.020161290322580645, 1]
[1.0, 52.0, 417.0, 5.0, 'type 1 diabetes. We subtracted  <estimates>  of type 1 from ', 0.017985611510791366, 1]
[1.0, 52.0, 426.0, 5.0, 'from overall diabetes to produce  <estimates>  for type 2 diabetes. ', 0.017421602787456445, 1]
[1.0, 52.0, 625.0, 5.0, 'The overarching limitation in cardiovascular  <estimation>  is that low-income and ', 0.0102880658436214, 1]
[1.0, 52.0, 748.0, 5.0, 'data sources that had lower  <estimates>  than the International Study ', 0.008210180623973728, 1]
[1.0, 53.0, 307.0, 5.0, 'falls. The WHO and GBD  <estimates>  on road injuries were ', 0.025510204081632654, 1]
[1.0, 53.0, 316.0, 5.0, 'were more similar, with WHO  <estimating>  20–50 million people experiencing ', 0.024390243902439025, 1]
[1.0, 53.0, 330.0, 5.0, 'year 89 and GBD 2017  <estimating>  54·2 million (47·4–61·6) road ', 0.0228310502283105, 1]
[1.0, 53.0, 347.0, 5.0, 'and GBD 2017 had similar  <estimates>  when comparisons were available—for ', 0.0211864406779661, 1]
[1.0, 53.0, 572.0, 5.0, 'is unlikely to provide improved  <estimates>  in the near future. ', 0.010845986984815618, 1]
[1.0, 53.0, 814.0, 5.0, 'data will not only inform  <estimates>  in terms of incidence ', 0.007112375533428165, 1]
[1.0, 53.0, 834.0, 5.0, 'accurate parameters that affect GBD  <estimates>  in other modelling steps. ', 0.006915629322268326, 1]
[1.0, 53.0, 850.0, 5.0, 'DisMod-MR 2.1, we start by  <estimating>  a global model that ', 0.006765899864682003, 1]
[1.0, 54.0, 76.0, 5.0, 'in 30-year-olds in 1990 when  <estimating>  prevalence in 50-year-olds in ', 0.08771929824561403, 1]
[1.0, 54.0, 262.0, 5.0, 'necessary part of the study’s  <estimation>  and reporting process, but ', 0.0205761316872428, 1]
[1.0, 54.0, 468.0, 5.0, 'and data that inform YLD  <estimation>  in the GBD study ', 0.011135857461024499, 1]
[1.0, 54.0, 532.0, 5.0, 'updated data sources for older  <estimation>  years but also to ', 0.009746588693957114, 1]
[1.0, 54.0, 543.0, 5.0, 'sources for the most recent  <estimation>  year. This necessitates data ', 0.009541984732824428, 1]
[1.0, 54.0, 635.0, 5.0, 'study’s ability to produce accurate  <estimates>  in the more recent ', 0.008116883116883116, 1]
[1.0, 54.0, 640.0, 5.0, 'estimates in the more recent  <estimation>  years. Relying more heavily ', 0.008051529790660225, 1]
[1.0, 54.0, 705.0, 5.0, 'plan to incorporate improved age-time  <estimation>  using a new tool, ', 0.007288629737609329, 1]
[1.0, 54.0, 756.0, 5.0, 'is the first year that  <estimates>  for a non-geo - ', 0.0067842605156037995, 1]
[1.0, 54.0, 785.0, 5.0, 'would be compelling to similarly  <estimate>  disease burden in groups ', 0.006527415143603133, 1]
[1.0, 66.0, 835.0, 5.0, 'the following categories: managing the  <estimation>  process; writing the first ', 0.007886435331230283, 1]
[1.0, 67.0, 1190.0, 5.0, 'Barrionuevo-Rosas L, et al. Global  <estimates>  of human papillomavirus vaccination ', 0.044642857142857144, 1]
[1.0, 69.0, 669.0, 5.0, 'and Projections Package model for  <estimating>  trends and current values ', 0.125, 1]
[1.0, 73.0, 288.0, 4.0, 'calculó con la fórmula para  <estimar>  la proporción y al ', 0.043478260869565216, 1]
[1.0, 69.0, 693.0, 3.0, 'Ciaranello A, et al. Improving  <estimates>  of children living with ', 0.046875, 1]
[1.0, 69.0, 693.0, 2.0, 'Ciaranello A, et al. Improving  <estimates>  of children living with ', 0.03125, 1]
[1.0, 54.0, 785.0, 1.0, 'would be compelling to similarly  <estimate>  disease burden in groups ', 0.0013054830287206266, 1]
[1.0, 3.0, 695.0, 1.0, 'and Central Statistical Office websites.  <Primary>  data sources containing disease ', 0.0017543859649122807, 1]
[1.0, 3.0, 754.0, 1.0, 'to data sources based on  <primary>  literature, surveys, and surveillance, ', 0.001589825119236884, 1]
[1.0, 15.0, 322.0, 1.0, '(−12·6 to −5·4)* Diagnosis and  <primary>  therapy phase of oesophageal ', 0.007751937984496124, 1]
[1.0, 15.0, 447.0, 1.0, '(−2·3 to 5·0) Diagnosis and  <primary>  therapy phase of stomach ', 0.003937007874015748, 1]
[1.0, 15.0, 574.0, 1.0, '(3·1 to 9·0)* Diagnosis and  <primary>  therapy phase of colon ', 0.0026246719160104987, 1]
[1.0, 16.0, 266.0, 1.0, '(1·5 to 9·2)* Diagnosis and  <primary>  therapy phase of liver ', 0.006944444444444444, 1]
[1.0, 16.0, 410.0, 1.0, '(2·9 to 12·1)* Diagnosis and  <primary>  therapy phase of liver ', 0.003472222222222222, 1]
[1.0, 16.0, 554.0, 1.0, '(12·4 to 20·9)* Diagnosis and  <primary>  therapy phase of liver ', 0.0023148148148148147, 1]
[1.0, 16.0, 694.0, 1.0, '(6·5 to 17·2)* Diagnosis and  <primary>  therapy phase of liver ', 0.0017482517482517483, 1]
[1.0, 17.0, 262.0, 1.0, '(1·8 to 7·6)* Diagnosis and  <primary>  therapy phase of pancreatic ', 0.0072992700729927005, 1]
[1.0, 17.0, 387.0, 1.0, '(0·0 to 5·6)* Diagnosis and  <primary>  therapy phase of larynx ', 0.003816793893129771, 1]
[1.0, 17.0, 540.0, 1.0, '(3·9 to 10·4)* Diagnosis and  <primary>  therapy phase of tracheal, ', 0.0024096385542168677, 1]
[1.0, 18.0, 432.0, 1.0, '(−6·8 to 1·8) Diagnosis and  <primary>  therapy phase of cervical ', 0.006493506493506494, 1]
[1.0, 18.0, 557.0, 1.0, '(1·9 to 8·2)* Diagnosis and  <primary>  therapy phase of uterine ', 0.0035842293906810036, 1]
[1.0, 19.0, 323.0, 1.0, '(4·1 to 14·1)* Diagnosis and  <primary>  therapy phase of testicular ', 0.006493506493506494, 1]
[1.0, 19.0, 448.0, 1.0, '(−6·3 to 1·6) Diagnosis and  <primary>  therapy phase of kidney ', 0.0035842293906810036, 1]
[1.0, 19.0, 560.0, 1.0, '(−1·4 to 3·3) Diagnosis and  <primary>  therapy phase of bladder ', 0.0025575447570332483, 1]
[1.0, 20.0, 256.0, 1.0, '(7·1 to 16·5)* Diagnosis and  <primary>  therapy phase of thyroid ', 0.0072992700729927005, 1]
[1.0, 20.0, 380.0, 1.0, '(−10·3 to 0·7) Diagnosis and  <primary>  therapy phase of mesothelioma9·1 ', 0.0038314176245210726, 1]
[1.0, 20.0, 501.0, 1.0, '(−2·2 to 6·5) Diagnosis and  <primary>  therapy phase of Hodgkin ', 0.002617801047120419, 1]
[1.0, 20.0, 626.0, 1.0, '(8·2 to 14·2)* Diagnosis and  <primary>  therapy phase of non-Hodgkin ', 0.0019723865877712033, 1]
[1.0, 21.0, 264.0, 1.0, '(0·3 to 33·7)* Diagnosis and  <primary>  therapy phase of acute ', 0.006711409395973154, 1]
[1.0, 21.0, 393.0, 1.0, '(2·5 to 12·3)* Diagnosis and  <primary>  therapy phase of chronic ', 0.0035971223021582736, 1]
[1.0, 21.0, 523.0, 1.0, '(−7·1 to 6·7) Diagnosis and  <primary>  therapy phase of acute ', 0.0024509803921568627, 1]
[1.0, 22.0, 286.0, 1.0, '(84·2 to 133·3)* Diagnosis and  <primary>  therapy phase of other ', 0.008771929824561403, 1]
[1.0, 49.0, 629.0, 1.0, 'age. While the efforts of  <primary>  prevention approaches such as ', 0.0019342359767891683, 1]
[1.0, 49.0, 737.0, 1.0, 'interventions as well as to  <primary>  prevention therapeutics could help ', 0.0016, 1]
[1.0, 62.0, 287.0, 1.0, 'Giampaoli MD); Unit of Academic  <Primary>  Care (Prof P S ', 0.00641025641025641, 1]
[1.0, 65.0, 739.0, 1.0, 'Health Policy & Center for  <Primary>  Care and Outcomes Research, ', 0.0015748031496062992, 1]
[1.0, 1.0, 341.0, 1.0, 'years. This study is a  <reassessment>  of the incidence, prevalence, ', 0.08333333333333333, 1]
[1.0, 52.0, 351.0, 1.0, 'instead reflects a more comprehensive  <assessment>  of acute malnutrition than ', 0.0047169811320754715, 1]
[1.0, 60.0, 1079.0, 1.0, 'and Information Technology, Health Technology  <Assessment>  Association, Moscow, Russia (A ', 0.1111111111111111, 1]
[1.0, 60.0, 1109.0, 1.0, 'of Research and Health Technology  <Assessment>  (F Castro MD), Gorgas ', 0.02564102564102564, 1]
[1.0, 3.0, 193.0, 1.0, 'and fertility rates have to  <match>  population rate change such ', 0.014705882352941176, 1]
[1.0, 0.0, 195.0, 1.0, '3484 sequelae. We used an  <updated>  and extensive body of ', 0.034482758620689655, 1]
[1.0, 0.0, 257.0, 1.0, 'were incorporated, as well as  <updated>  claims data from the ', 0.01098901098901099, 1]
[1.0, 0.0, 329.0, 1.0, 'sequela, adjusted for comorbidity. We  <updated>  the Socio-demographic Index (SDI), ', 0.006134969325153374, 1]
[1.0, 0.0, 351.0, 1.0, 'total fertility rate. Additionally, we  <calculated>  differences between male and ', 0.005405405405405406, 1]
[1.0, 1.0, 525.0, 1.0, 'aetiological attribution; for HIV/AIDS, we  <updated>  absolute neutrophil count bias ', 0.00510204081632653, 1]
[1.0, 1.0, 608.0, 1.0, 'to estimate incidence, and then  <calculated>  prevalence on the basis ', 0.0035842293906810036, 1]
[1.0, 1.0, 632.0, 1.0, 'covariates for opioid use and  <updated>  autism spectrum disorder designations ', 0.0033003300330033004, 1]
[1.0, 2.0, 847.0, 1.0, 'estimates for these countries were  <incorporated>  into model development and ', 0.001440922190201729, 1]
[1.0, 3.0, 594.0, 1.0, 'and one impairment, which were  <updated>  to Feb 11, 2018. ', 0.0021321961620469083, 1]
[1.0, 3.0, 654.0, 1.0, 'in non-fatal estimation, reflecting our  <updated>  counting criteria for GBD ', 0.001890359168241966, 1]
[1.0, 3.0, 679.0, 1.0, 'suggested by country-level experts, surveys  <located>  in multinational survey data ', 0.0018050541516245488, 1]
[1.0, 4.0, 312.0, 1.0, 'section 4). Custom models were  <created>  if DisMod-MR 2.1 did ', 0.00510204081632653, 1]
[1.0, 4.0, 332.0, 1.0, 'and prevalence needed to be  <calculated>  from other data, or ', 0.004629629629629629, 1]
[1.0, 5.0, 157.0, 1.0, 'disability weight, the health loss  <associated>  with two disability weights ', 0.030303030303030304, 1]
[1.0, 5.0, 592.0, 1.0, 'under 25 years remains highly  <correlated>  with mortality measures including ', 0.002136752136752137, 1]
[1.0, 5.0, 620.0, 1.0, 'from GBD 2016 are also  <correlated>  (r =0·992). 24 We ', 0.0020161290322580645, 1]
[1.0, 29.0, 571.0, 1.0, 'to 22·5)*4·0% (−0·1 to 8·6)  <Uncomplicated>  type 2 diabetes mellitus263 ', 0.008620689655172414, 1]
[1.0, 42.0, 956.0, 1.0, 'so progress in SDI is  <associated>  with points further to ', 0.0011185682326621924, 1]
[1.0, 48.0, 714.0, 1.0, 'and depressive disorders can be  <treated>  with low-cost therapeutics. The ', 0.007352941176470588, 1]
[1.0, 48.0, 828.0, 1.0, '2017 (figure 3). Diabetes poses  <complicated>  care challenges even in ', 0.004, 1]
[1.0, 50.0, 716.0, 1.0, 'globally, YLD counts are heavily  <concentrated>  in working-age males and ', 0.0026455026455026454, 1]
[1.0, 51.0, 90.0, 1.0, 'sexes combined. If anaemia were  <treated>  as a cause, it ', 0.012987012987012988, 1]
[1.0, 51.0, 547.0, 1.0, 'year-specific estimates of risk factors  <associated>  with diarrhoea or LRI. ', 0.0018726591760299626, 1]
[1.0, 51.0, 629.0, 1.0, 'compared with GBD 2016. We  <updated>  our inputs of antiretroviral ', 0.0016233766233766235, 1]
[1.0, 52.0, 314.0, 1.0, 'malnutrition past age 5 years,  <incorporated>  cause-specific mortality rates, and ', 0.005714285714285714, 1]
[1.0, 53.0, 769.0, 1.0, 'This year, we also used  <tabulated>  claims records from Taiwan ', 0.001519756838905775, 1]
[1.0, 54.0, 410.0, 1.0, 'data, and additionally we have  <incorporated>  input from the GBD ', 0.0025575447570332483, 1]
[1.0, 54.0, 504.0, 1.0, 'directions are planned to be  <incorporated>  in the coming cycles. ', 0.002061855670103093, 1]
[1.0, 54.0, 527.0, 1.0, 'will be important to incorporate  <updated>  data sources for older ', 0.001968503937007874, 1]
[1.0, 54.0, 562.0, 1.0, 'year in order to be  <incorporated>  for the following year’s ', 0.001841620626151013, 1]
[1.0, 62.0, 401.0, 1.0, 'Social Affairs, Government of the  <Federated>  States of Micronesia, Palikir, ', 0.003703703703703704, 1]
[1.0, 62.0, 406.0, 1.0, 'Federated States of Micronesia, Palikir,  <Federated>  States of Micronesia (S ', 0.0036363636363636364, 1]
[1.0, 66.0, 966.0, 1.0, 'Boris Bikbov acknowledges that work  <related>  to this paper has ', 0.00130718954248366, 1]
[1.0, 68.0, 472.0, 1.0, 'X, et al . Factors  <associated>  with hypertension awareness, treatment, ', 0.0029069767441860465, 1]
[1.0, 68.0, 895.0, 1.0, 'risk in secondary prevention patients  <treated>  with high- versus low-dose ', 0.001303780964797914, 1]
[1.0, 68.0, 924.0, 1.0, 'Capewell S. Mortality risk reduction  <associated>  with smoking cessation in ', 0.001256281407035176, 1]
[1.0, 52.0, 346.0, 1.0, 'of protein-energy malnutrition cases, it  <instead>  reflects a more comprehensive ', 0.004830917874396135, 1]
[1.0, 82.0, 186.0, 4.0, 'lo que concuerda con lo  <expresado>  por Torres-Martínez et al. ', 0, 0]
[1.0, 67.0, 559.0, 3.0, 'for International Development (USAID). Views  <expressed>  do not necessarily reflect ', 0, 0]
[1.0, 67.0, 559.0, 2.0, 'for International Development (USAID). Views  <expressed>  do not necessarily reflect ', 0, 0]
[1.0, 70.0, 149.0, 2.0, 'se concentra en la subregión  <exprovincia>  Obando al sur del ', 0, 0]
[1.0, 71.0, 97.0, 2.0, 'is concentrated in the Obando  <exprovincia>  subregion to the south ', 0, 0]
[1.0, 72.0, 83.0, 2.0, '1995, la subregión conocida como  <exprovincia>  Obando (se encuentran municipios ', 0, 0]
[1.0, 73.0, 196.0, 2.0, 'Puerres, pertenecientes a la subregión  <exprovincia>  de Obando del departamento ', 0, 0]
[1.0, 62.0, 131.0, 1.0, 'Medicine and Global Health (S  <Lewycka>  PhD), Nuffield Department of ', 0, 0]
[1.0, 63.0, 1169.0, 1.0, 'Asia Programme, Hanoi, Vietnam (S  <Lewycka>  PhD); Department of Clinical ', 0, 0]
[1.0, 76.0, 54.0, 1.0, 'el 41 % de las  <respuestas>  indican que reciben más ', 0, 0]
[1.0, 1.0, 74.0, 1.0, 'In parallel with the increasing  <complexity>  of clinical medicine in ', 0, 0]
[1.0, 49.0, 112.0, 1.0, 'metabolic conditions globally. Given the  <complexity>  of chronic liver disease ', 0, 0]
[1.0, 58.0, 1143.0, 1.0, 'MD), Student Research Committee (M  <Khosravi>  MD), Baqiyatallah University of ', 0, 0]
[1.0, 63.0, 641.0, 1.0, 'Research Association, Tehran, Iran (M  <Khosravi>  MD); Clinical Epidemiology Unit ', 0, 0]
[1.0, 38.0, 245.0, 6.0, 'for the leading six impairments  <estimated>  in GBD: anaemia, heart ', 0, 0]
[1.0, 50.0, 38.0, 6.0, 'the USA, opioid dependence was  <estimated>  to cause more than ', 0, 0]
[1.0, 51.0, 13.0, 6.0, '2018if it was not also  <estimated>  in aggregate. In 2017, ', 0, 0]
[1.0, 53.0, 48.0, 6.0, 'haemopoietic neoplasms”, which were previously  <estimated>  as part of the ', 0, 0]
[1.0, 53.0, 82.0, 6.0, 'and substance use disorders We  <estimated>  burden for a combined ', 0, 0]
[0.0, 0.0, 0.0, 0.0, '0', 0, 0]
[1.0, 0.0, 166.0, 5.0, 'include increasing the level of  <estimation>  detail, improving analytical strategies, ', 0, 0]
[1.0, 1.0, 329.0, 5.0, 'the study have increased the  <estimation>  detail for conditions, locations, ', 0, 0]
[1.0, 3.0, 41.0, 5.0, 'main text (appendix 2). Subnational  <estimates>  for countries with populations ', 0, 0]
[1.0, 3.0, 70.0, 5.0, 'published elsewhere are presented wherever  <estimates>  are illustrated with maps ', 0, 0]
[1.0, 3.0, 86.0, 5.0, 'tables. Cause-specific results for non-fatal  <estimates>  for GBD 2017 cover ', 0, 0]
[1.0, 3.0, 125.0, 5.0, 'is the first time that  <estimation>  of fertility and population ', 0, 0]
[1.0, 4.0, 65.0, 5.0, 'by providing incidence and prevalence  <estimates>  adjusted for read mission, ', 0, 0]
[1.0, 4.0, 85.0, 5.0, 'the above, but also by  <estimating>  parameters such as case ', 0, 0]
[1.0, 5.0, 75.0, 5.0, '1 section 4). Disability weight  <estimation>  is described in more ', 0, 0]
[1.0, 5.0, 124.0, 5.0, 'health states used in the  <estimation>  of non-fatal results for ', 0, 0]
[1.0, 6.0, 28.0, 5.0, 'Table 1 reports cause-specific global  <estimates>  of prevalence, incidence, and ', 0, 0]
[1.0, 39.0, 498.0, 5.0, 'by SDI quintile, 1990–2017 Mean  <estimates>  are shown. SDI=Socio-demographic Index. ', 0, 0]
[1.0, 52.0, 139.0, 5.0, 'our inpatient admission per -capita  <estimates>  to include in- facility ', 0, 0]
[1.0, 53.0, 15.0, 5.0, 'disorders, although in future studies,  <estimates>  of neurological disorders will ', 0, 0]
[1.0, 53.0, 111.0, 5.0, '2017 as opposed to separately  <estimating>  autism and Asperger’s syndrome ', 0, 0]
[1.0, 54.0, 19.0, 5.0, 'cascade. Time trends in our  <estimates>  result from where the ', 0, 0]
[1.0, 67.0, 1078.0, 5.0, 'A comparison of maternal mortality  <estimates>  from GBD 2013 and ', 0, 0]
[1.0, 68.0, 128.0, 5.0, 'for accurate and transparent health  <estimates>  reporting: the GATHER statement. ', 0, 0]
[1.0, 69.0, 629.0, 5.0, 'of childhood pneumonia in 2010:  <estimates>  of incidence, severe morbidity, ', 0, 0]
[1.0, 72.0, 171.0, 3.0, 'Colombia - MADR (2020), se  <estima>  que en la actualidad ', 0, 0]
[1.0, 56.0, 39.0, 1.0, 'Johnson, Jost B Jonas, Jacek  <Jerzy>  Jozwiak, Suresh Banayya Jungari, ', 0, 0]
[1.0, 14.0, 572.0, 1.0, '(4·7 to 13·4)* Diagnosis and  <primary>  therapy phase of mouth ', 0, 0]
[1.0, 15.0, 67.0, 1.0, '(−7·0 to 4·5) Diagnosis and  <primary>  therapy phase of nasopharynx ', 0, 0]
[1.0, 15.0, 193.0, 1.0, '(4·4 to 16·9)* Diagnosis and  <primary>  therapy phase of other ', 0, 0]
[1.0, 16.0, 122.0, 1.0, '(2·5 to 17·0)* Diagnosis and  <primary>  therapy phase of liver ', 0, 0]
[1.0, 17.0, 125.0, 1.0, '(−3·7 to 6·8) Diagnosis and  <primary>  therapy phase of gallbladder ', 0, 0]
[1.0, 18.0, 68.0, 1.0, '(0·9 to 8·6)* Diagnosis and  <primary>  therapy phase of malignant ', 0, 0]
[1.0, 18.0, 278.0, 1.0, '(0·7 to 7·5)* Diagnosis and  <primary>  therapy phase of breast ', 0, 0]
[1.0, 19.0, 43.0, 1.0, 'from previous page) Diagnosis and  <primary>  therapy phase of ovarian ', 0, 0]
[1.0, 19.0, 169.0, 1.0, '(2·1 to 13·2)* Diagnosis and  <primary>  therapy phase of prostate ', 0, 0]
[1.0, 20.0, 119.0, 1.0, '(17·7 to 32·8)* Diagnosis and  <primary>  therapy phase of brain ', 0, 0]
[1.0, 21.0, 115.0, 1.0, '(5·9 to 14·7)* Diagnosis and  <primary>  therapy phase of multiple ', 0, 0]
[1.0, 22.0, 43.0, 1.0, 'from previous page) Diagnosis and  <primary>  therapy phase of chronic ', 0, 0]
[1.0, 22.0, 172.0, 1.0, '(−9·7 to 1·9) Diagnosis and  <primary>  therapy phase of other ', 0, 0]
[1.0, 59.0, 1364.0, 1.0, 'of General Internal Medicine and  <Primary>  Care (Prof A Sheikh ', 0, 0]
[1.0, 60.0, 625.0, 1.0, 'C Davis PhD), Department of  <Primary>  Care and Public Health ', 0, 0]
[1.0, 61.0, 217.0, 1.0, 'Department of Public Health and  <Primary>  Care, University of Cambridge, ', 0, 0]
[1.0, 63.0, 864.0, 1.0, 'of Global Public Health and  <Primary>  Care (Prof O F ', 0, 0]
[1.0, 0.0, 68.0, 1.0, '(GBD 2017) includes a comprehensive  <assessment>  of incidence, prevalence, and ', 0, 0]
[1.0, 60.0, 1070.0, 1.0, 'Geneva, Switzerland; Committee for Comprehensive  <Assessment>  of Medical Devices and ', 0, 0]
[1.0, 65.0, 104.0, 1.0, 'The Center for Healthcare Quality  <Assessment>  and Control, Ministry of ', 0, 0]
[1.0, 66.0, 201.0, 1.0, 'MD); Agency for Health Technology  <Assessment>  and Tariff System, Warszawa, ', 0, 0]
[1.0, 1.0, 43.0, 1.0, 'and injuries being diagnosed and  <treated>  in individual patients, and ', 0, 0]
[1.0, 1.0, 87.0, 1.0, 'measuring non-fatal health loss has  <necessitated>  continuous refinement as diagnostic ', 0, 0]
[1.0, 2.0, 47.0, 1.0, 'life-years (DALYs), evolves toward being  <dominated>  by years lived with ', 0, 0]
[1.0, 2.0, 68.0, 1.0, 'areas of the world have  <created>  dynamic temporal patterns, particularly ', 0, 0]
[1.0, 2.0, 153.0, 1.0, 'Factors Study (GBD) have also  <illustrated>  differential health outcomes in ', 0, 0]
[1.0, 3.0, 72.0, 1.0, 'are presented wherever estimates are  <illustrated>  with maps but are ', 0, 0]
[1.0, 4.0, 116.0, 1.0, 'the clinical data adjustments are  <calculated>  and how admission and ', 0, 0]
[1.0, 5.0, 96.0, 1.0, 'the severity of health loss  <associated>  with a single given ', 0, 0]
[1.0, 13.0, 683.0, 1.0, 'to −5·0)*−5·9% (−9·5 to −2·0)*  <Uncomplicated>  preterm birth13 715·6 (12 ', 0, 0]
[1.0, 29.0, 455.0, 1.0, 'to 4·9)*−1·2% (−2·3 to −0·1)*  <Uncomplicated>  type 1 diabetes mellitus8762·6 ', 0, 0]
[1.0, 42.0, 62.0, 1.0, 'causes of non-fatal health loss,  <calculated>  as the female-specific estimate ', 0, 0]
[1.0, 43.0, 970.0, 1.0, '2 causes between sexes were  <calculated>  using the values for ', 0, 0]
[1.0, 48.0, 578.0, 1.0, 'loss. These patterns are probably  <related>  to population growth and ', 0, 0]
[1.0, 50.0, 338.0, 1.0, 'YLDs experienced by females. As  <indicated>  by the higher Z ', 0, 0]
[1.0, 55.0, 130.0, 1.0, 'middle ages, where it is  <speculated>  that non-fatal health loss ', 0, 0]
[1.0, 71.0, 71.0, 1.0, 'the last 15 years, the  <cultivated>  area in the country ', 0, 0]
[1.0, 71.0, 93.0, 1.0, 'production; the producing area is  <concentrated>  in the Obando exprovincia ', 0, 0]
[1.0, 71.0, 107.0, 1.0, 'of the department and is  <cultivated>  mainly by smallholdings. This ', 0, 0]
[1.0, 3.0, 32.0, 1.0, 'in appendix tables and figures  <instead>  of in the main ', 0, 0]
